ORINDA,
Calif., May 6, 2024 /PRNewswire/ -- CG
Pharmaceuticals, a late-stage clinical biopharmaceutical company
specializing in metastatic pancreatic ductal adenocarcinoma
(PDAC) maintenance therapy (NCT05249101), will feature one of our
investigators, Dr. Christos Fountzilas from Roswell Park
Comprehensive Cancer Center, at the ASCO Annual Meeting in
Chicago on June 1st, 1:30 – 4:30 PM
CDT, during the Gastrointestinal Cancer session (TPS4206).
He will be presenting some of the findings from our completed Phase
1b and study design of the on-going
Phase 2 clinical trial. Commencement of treatment for the first
patient of Phase 2 began on January 9th,
2024, and the study will continue to recruit patients in
approximately 25 institutions throughout the US.
CG Pharmaceuticals, Inc. to Present at the
2024 ASCO Annual Meeting in Chicago on June
1st
In the Phase 2 study, metastatic PDAC patients who show no
evidence of disease progression after treatment with FOLFIRINOX,
mFOLFIRINOX or NALIRIFOX will receive either the
ivaltinostat/capecitabine combination therapy or capecitabine
monotherapy after randomization. The primary endpoint is to
evaluate ivaltinostat's effect on improving progression free
survival (PFS), while key secondary endpoints include objective
response rate (ORR), disease control rate (DCR), and overall
survival (OS).
About Ivaltinostat:
Ivaltinostat is a potential first-in-class novel therapeutic
candidate for pancreatic ductal adenocarcinoma that inhibits
enzymatic activity of histone deacetylase and has been evaluated
for solid tumors and hematologic malignancies.
About CG Pharmaceuticals:
CG Pharmaceuticals is a late-stage clinical biopharmaceutical
company that is dedicated to advancing innovative therapies to
improve the lives of patients with cancer. CG Pharmaceuticals is
located in the San Francisco Bay Area.
Forward-Looking Statement Disclosure:
This press release may contain certain forward-looking
statements relating to the goals, business strategy, financial and
market position, product development, and projections for the
Company. Such forward-looking statements are based on current
expectations and involve inherent risks and uncertainties,
including factors that could delay, divert or change any of them,
and could cause actual outcomes and results to differ materially
from current expectations. No forward-looking statements can be
guaranteed, and actual results may differ. The information in this
release is provided only as of the written date, and CG
Pharmaceuticals undertakes no obligation to update any
forward-looking statements contained in this release, except as
required by law.
CG Pharmaceuticals Contact:
Douglas An
Head of Finance and IR Representative
douglas.an@cgpharma.com
View original
content:https://www.prnewswire.com/news-releases/cg-pharmaceuticals-inc-to-present-at-the-2024-asco-annual-meeting-in-chicago-on-june-1st-302136351.html
SOURCE CG Pharmaceuticals, Inc.